PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) narrowed its second-quarter net loss as the biotechnology company moved its lead drug candidate toward an Oct. 30 regulatory decision and raised additional …
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.